Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 0.71 |
| ▸ | KDR | P35968 | 20/20 | 0.71 |
| ▸ | FLT3 | P36888 | 14/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | BLK | P51451 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423729 | 0.85 | KIT (0.86) | KITKDRFLT3ABL1LCK | |
| SCHEMBL5425615 | 0.83 | KIT (0.74) | KITKDRFLT3ABL1LCK | |
| SCHEMBL420436 | 0.83 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL425177 | 0.83 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL421700 | 0.83 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL422109 | 0.82 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL421890 | 0.82 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL420513 | 0.82 | KIT (0.76) | KITKDRFLT3ABL1LCK | |
| SCHEMBL31531260 | 0.82 | KIT (1.00) | KITKDRFLT3ABL1LCK | |
| SCHEMBL420317 | 0.82 | KIT (1.00) | KITKDRFLT3ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1850839-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON INC. (CH) | 2007-11-07 | — | — | EP | claimed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | claimed |